Gilead Sciences, Inc. (GILD)

Market Cap	150.84B
Revenue (ttm)	29.09B
Net Income (ttm)	8.11B
Shares Out	1.24B
EPS (ttm)	6.42
PE Ratio	18.93
Forward PE	14.37
Dividend	$3.16 (2.60%)
Ex-Dividend Date	Dec 15, 2025

Volume	2,904,062
Open	122.29
Previous Close	122.62
Day's Range	120.38 - 122.53
52-Week Range	88.57 - 128.70
Beta	0.33
Analysts	Buy
Price Target	123.45 (+1.54%)
Earnings Date	Oct 30, 2025

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Jan 22, 1992
• Employees: 17,600
• Stock Exchange: NASDAQ
• Ticker Symbol: GILD
• Website: https://www.gilead.com

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Analyst Summary

According to 22 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $123.45, which is an increase of 1.54% from the latest price.

Price Target

$123.45

(1.54% upside)

Analyst Consensus: Buy